Skip to main content

Table 1 Inclusion and exclusion criteria

From: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series

Inclusion criteria Exclusion criteria
• Histological diagnosis of high-grade glioma (WHO grade III or IV)
• Announcement of a diagnosis
• Positive genomic DNA typing test for HLA-A*2402 (HLA Laboratory, Kyoto, Japan)
• Age between 16 and 79
• Eastern Cooperative Oncology (ECOG) performance status (PS) 0–2
• Completion of standard treatment (surgical removal + radiotherapy concomitant with temozolomide)
• No prior surgery, irradiation, or chemotherapy 4 weeks before entry to the study
• No uncontrollable pleural, peritoneal or cardiac effusion
• Life expectancy > 3 months
• Written informed consents are obtained.
Lab values prior to vaccine
• Neutrophil count ≥1000/mm3
• Platelet count ≥500,00/mm3
• Hemoglobin level ≥ 8.0 g/dl, a
• Aspartate aminotransferase and alanine aminotransferase ≤4.0x the institutional normal upper limits
• Total bilirubin ≤1.5x
• Creatinine ≤2.0 mg/dL
• No uncontrollable pleural, peritoneal or cardiac effusion
• The presence of uncontrollable severe infectious diseases
• Adverse event of National Cancer Institute - Common Toxicity Criteria (NCI-CTC) grade 3 or 4
• Unable to take anything orally over 24 h
• Other uncontrolled malignant diseases
• Myeloproliferative diseases
• After allogeneic hematopoietic stem cell transplantation
• Active autoimmune diseases
• Severe drug allergy
• Concurrent treatment with steroids or immunosuppressive agents
• Pregnant women or patients who planned to become pregnant during the study period
• Psychiatric disorders
• Unhealed wound
• Decision of unsuitability by the principal investigator or the physician in charge.